Insulin analogue: Difference between revisions
Removed redirect to Insulin analog Tag: Removed redirect |
No edit summary |
||
| Line 1: | Line 1: | ||
{{Infobox drug | {{Infobox drug | ||
| name = Insulin analog | | name = Insulin analog | ||
| pronounce = | | pronounce = | ||
| tradename = [[Humalog]], [[NovoLog]], [[Lantus]], [[Levemir]], [[Tresiba]], [[Fiasp]], [[Apidra]], and others | | tradename = [[Humalog]], [[NovoLog]], [[Lantus]], [[Levemir]], [[Tresiba]], [[Fiasp]], [[Apidra]], and others | ||
Revision as of 15:46, 13 March 2025
| Insulin analogue | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | Insulin preparation |
| Routes of administration | Subcutaneous injection, IV (for some rapid-acting analogs) |
| Pregnancy category | Varies by analog |
| Bioavailability | Varies |
| Metabolism | Liver, kidney |
| Elimination half-life | Varies (minutes to hours) |
| Excretion | Kidney |
| Legal status | Rx-only |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Insulin analogs are modified forms of human insulin designed to improve pharmacokinetics and pharmacodynamics, providing better glycemic control for people with diabetes mellitus. These synthetic insulins have altered amino acid sequences, affecting their absorption, distribution, metabolism, and elimination (ADME) properties.
Types of Insulin Analogs
Insulin analogs are classified into rapid-acting, long-acting, and ultra-long-acting formulations based on their onset and duration of action.
Rapid-acting Insulin Analogs
Used to control postprandial blood glucose spikes.
| Name | Brand Names | Onset of Action | Peak Effect | Duration |
|---|---|---|---|---|
| Insulin lispro | Humalog, Admelog | ~15 min | 1–2 hours | 3–5 hours |
| Insulin aspart | NovoLog, Fiasp | ~10–20 min | 1–3 hours | 3–5 hours |
| Insulin glulisine | Apidra | ~15 min | 1–2 hours | 3–5 hours |
Long-acting and Ultra-long-acting Insulin Analogs
Used to maintain basal insulin levels throughout the day.
| Name | Brand Names | Onset of Action | Peak Effect | Duration |
|---|---|---|---|---|
| Insulin glargine | Lantus, Toujeo, Basaglar | ~1–2 hours | No significant peak | 18–24 hours |
| Insulin detemir | Levemir | ~1–2 hours | Minimal peak | 12–24 hours |
| Insulin degludec | Tresiba | ~1 hour | No significant peak | >42 hours |
Mechanism of Action
Insulin analogs work by: 1. Binding to the insulin receptor (IR) on target cells (liver, muscle, adipose). 2. Stimulating glucose uptake via GLUT4 transporters. 3. Inhibiting hepatic glucose production and promoting glycogen synthesis. 4. Suppressing lipolysis and proteolysis.
The modifications in insulin analogs affect their absorption rate and receptor affinity, providing a more physiological insulin profile.
Advantages of Insulin Analogs
Compared to human insulin, insulin analogs offer:
- Faster onset (e.g., rapid-acting analogs for meal coverage).
- Prolonged basal action (e.g., ultra-long-acting insulin reduces nocturnal hypoglycemia).
- Lower risk of hypoglycemia (especially long-acting formulations).
- More predictable absorption with less variability.
Clinical Indications
Insulin analogs are used for:
- Type 1 diabetes mellitus (T1DM) – Requires both basal and bolus insulin.
- Type 2 diabetes mellitus (T2DM) – Used when oral hypoglycemic agents fail.
- Gestational diabetes mellitus (GDM) – Preferred over human insulin for better glycemic control.
- Diabetic ketoacidosis (DKA) – IV insulin analogs used in critical care settings.
Comparison with Human Insulin
| Feature | Human Insulin | Insulin Analogs |
|---|---|---|
| Onset of action | Slower (30–60 min) | Faster (10–15 min for rapid-acting) |
| Duration | Shorter or longer (varies) | More predictable |
| Risk of hypoglycemia | Higher | Lower (especially nocturnal hypoglycemia) |
| Absorption variability | Higher | Lower |
Potential Side Effects
Common side effects include:
- Hypoglycemia (risk varies by type of insulin).
- Weight gain (due to anabolic effects of insulin).
- Injection site reactions (e.g., lipodystrophy).
- Allergic reactions (rare but possible).
- Hypokalemia (can lead to cardiac arrhythmias).
Special Considerations
- Renal impairment – Adjust dosing for patients with chronic kidney disease (CKD).
- Liver dysfunction – Insulin metabolism is reduced in hepatic impairment.
- Pregnancy and lactation – Some analogs (e.g., insulin detemir) are FDA-approved for pregnancy.
Future Developments
Research is ongoing for:
- Oral insulin formulations (to improve compliance).
- Smart insulin pumps (automated insulin delivery systems).
- Ultra-rapid insulins (faster onset for meal-time control).